Anti-PD-1/PD-L1 antibodies work by binding to the inhibitory PD-1 receptors on tumor-reactive T cells and PD-L1 on tumor cells, respectively, to disrupt the PD-1/PD-L1 interaction and reactivate the cytotoxic T cell activity. The gene discussed is CD274; the disease is neoplasm.